Roche's cobas KRAS Mutation Test has been awarded CE mark approval for identifying colorectal cancer.
The cobas KRAS Mutation test identifies mutations in the KRAS gene of colorectal cancer tissues that are predictive of individual response to therapy with anti-epidermal growth factor receptor (EGFR) antibody therapies.
The cobas test is a TaqMelt polymerase chain reaction-based diagnostic test intended for the detection of mutations in codons 12, 13 and 61 of the KRAS gene with high sensitivity.
Roche Molecular Systems head Paul Brown said the cobas KRAS Mutation Test provides oncology professionals with a new, validated tool to help guide and personalise treatment of colorectal cancer.